8th 3D Tissue Models Summit 2023

Memo

Following the excitement behind President Biden signing the FDA modernization Act 2.0 in December 2022, Hesperos and Sanofi successfully getting IND approval from organ-on-chip data for a Phase2 clinical trial, and NIH bioprinting eye tissue to develop in vitro models of AMD, the , the 8th Annual 3D Tissue Models Summit will return to Boston in May 2023 to reunite the community of drug discovery and development experts. This is the definitive meeting for drug developers to explore and integrate complex 3D models featuring 24+ real-life case studies across 2 dedicated tracks and their lessons learned. URLs:Tickets: https://go.evvnt.com/1511989-2?pid=5569 Brochure: https://go.evvnt.com/1511989-3?pid=5569  Date and Time: On Tue, 16 May 2023 09:00 - Thu, 18 May 2023 16:00 Venue details: Hilton Boston Back Bay, 40 Dalton Street, Boston, Massachusetts, 02115, United States Prices:Conference Only - Drug Developer Pricing: USD 2999.00,Conference + 1 Workshop - Drug Developer Pricing: USD 3648.00,Conference + 2 Workshops - Drug Developer Pricing: USD 4297.00,Conference Only - Academic Pricing: USD 2599.00,Conference + 1 Workshop - Academic Pricing: USD 3148.00,Conference + 2 Workshops - Academic Pricing: USD 3697.00,Conference Only - Solution Provider Pricing: USD 3799.00,Conference + 1 Workshop - Solution Provider Pricing: USD 4548.00,Conference + 2 Workshops - Solution Provider Pricing: USD 5297.00 Speakers: Adriana Martinez Ledo, Principal Scientist, Norvartis, Anastasia Korolj, Postdoctoral Research Fellow, Harvard Medical School, Anirban Chatterjee Director, Advanced Cell Culture Services, MilliporeSigma, Barbara Diaz-Rohrer, Postdoctoral Associate, Broad Institute, Beth Hoffman, Founder and Chief Executive Officer, Origami Therapeutics, David Zhang, Co-founder and Chief Scientific Officer, Revela, Esmaiel Jabbari, Professor of Chemical and Biomedical Engineering, University of South Carolina, Haiyan Peng, Principal Scientist, Alnylam Pharmaceuticals, Ingrid Lua, Associate Director, AstraZeneca, James Hickman, Professor, University of Central Florida, Joe Kissil, Chair of Molecular Oncology, Moffitt Cancer Center, Katherin Patsch, Drug Discovery Project Manager, Ellison Institue, Kenneth Pryde, Associate Director, Oncology Safety Sciences, AstraZeneca, Lena Smirnova, Assistant Professor, Johns Hopkins University, Magdalena Kasendra, Director of Research and Development, Cincinnati Children's Hospital, Matthias von Herrath, Vice President and Senior Medical Officer, Global Chief Medical Office, Novo Nordisk, Min Jae Song, Staff Scientist, NCATS, Ratnakar Potla, Principal Scientist, Genentech, Remi Villenave, Lab Head, Roche, Richard Cheng, Post-doctoral Fellow, Harvard Medical School, Richard Hanna, Associate Director Bioscience Immunology, AstraZeneca, Roger Kamm, Professor, MIT, Sumeer Dhar, Director, Scientific Alliances, SCREEN Holdings, Tuyen Nguyen, Principal Scientist, Alnylam Pharmaceuticals